Serina Therapeutics CEO to Present on SER-252 Progress for Advanced Parkinson’s
Event summary
- Serina Therapeutics CEO Steven Ledger to present at Tribe Public’s webinar on September 24, 2026.
- Event focuses on clinical progress of SER-252, a long-acting treatment for advanced Parkinson’s disease.
- Registration open at AdvancingParkinsonsDisease.TribePublic.com.
- Tribe Public’s membership includes family offices, portfolio managers, and accredited investors.
The big picture
Serina Therapeutics is positioning itself as a key player in the treatment of advanced Parkinson’s disease, an area with no major clinical advances in over 50 years. The company’s POZ Platform technology aims to enhance the efficacy and safety of neurological treatments, potentially disrupting the current market dynamics. The upcoming webinar is a strategic move to engage investors and analysts, highlighting the progress of its lead candidate, SER-252.
What we're watching
- Clinical Milestones
- The pace at which SER-252 advances through clinical trials will determine its market potential.
- Investor Sentiment
- How investor interest translates into funding or partnerships following the presentation.
- Competitive Positioning
- Whether Serina can differentiate SER-252 in a landscape with limited recent advancements in Parkinson’s treatment.
Related topics